ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
This article is part of the Research TopicData and Precision: AI Leading the Revolution in Immunoradiotherapy for Advanced Malignant TumorsView all 3 articles
Performance of AI-based machine learning models for overall survival prediction in advanced hepatocellular carcinoma patients receiving immunoradiotherapy
Provisionally accepted- 1Henan Provincial People's Hospital, Zhengzhou, China
- 2Boxing People's Hospital, Binzhou, China
- 3Changzhi Medical College, Changzhi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. Although immunotherapy and targeted therapy have improved survival in advanced HCC, outcomes remain heterogeneous. Radiotherapy (RT) may enhance systemic treatment efficacy through local control and immunomodulation. Artificial intelligence (AI) offers opportunities to integrate multimodal data for individualized prognostic assessment. Methods: A total of 175 HCC patients were included in this study: 115 in the RT group (RT + immunotherapy + targeted therapy) and 60 in the non-RT group (immunotherapy + targeted therapy). Baseline characteristics were analyzed with chi-square and Mann–Whitney U tests. Overall survival (OS) was compared using the Kaplan–Meier method and log-rank test. Patients were randomly divided into a training cohort and a validation cohort (6:4 ratio). Prognostic factors were identified in the training cohort and incorporated into 101 machine learning (ML) algorithms. Model performance was assessed using the concordance index (C-index), receiver operating characteristic (ROC) curves, and risk score stratification. Results: The RT group achieved significantly longer OS than the non-RT group (median OS: 15.4 vs. 8.5 months, P = 0.003). Four variables ("Child," "BCLC stage," "Size," and "Treatment") were identified as prognostic factors. Among 101 ML models, the StepCox (forward) + Ridge model showed the best performance (C-index: 0.68 in training, 0.65 in validation). Time-dependent ROC analysis demonstrated AUC values of 0.72, 0.75, and 0.74 at 1-, 2-, and 3-year OS in the training cohort, and 0.72, 0.75, and 0.73 in the validation cohort, respectively. Conclusion: RT significantly improved prognosis in advanced HCC patients treated with immunotherapy and targeted therapy. Among multiple algorithms, the StepCox (forward) + Ridge model achieved superior predictive performance, supporting its potential value in individualized prognostic assessment.
Keywords: artificial intelligence, Machine learning model, Hepatocellular Carcinoma, immunoradiotherapy, targeted therapy
Received: 06 Oct 2025; Accepted: 14 Nov 2025.
Copyright: © 2025 Ke, Xiao, Wang, Luo and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Shanbao Ke, x18716189260@163.com
Jianwei Zhou, 18037790277@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
